Propel previously shared a billing code with Intersect ENT’s Sinuva implant, the release said. The new approval establishes a separate code for Propel and updates Sinuva’s J-Code to J7402.
Propel products are the first and only bioabsorbable steroid-releasing sinus implants approved by the FDA to maintain patency and locally deliver steroids to adults after sinus surgery, the release said.
More articles on healthcare:
Ophthalmologist convicted of $73M billing fraud has 17-year sentence commuted by Trump
What hospitals posting rates online means for ASCs
Optum reports revenue of $35.9B in Q4, $136.3B in 2020 — 6 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
